Peregrine Pharmaceuticals Down 6.1%, Shares Slide into the Red (PPHM)
Comtex SmarTrend(R) - Mon Dec 15, 12:42PM CST
Peregrine Pharmaceuticals (NASDAQ
PPHM: 1.40 (+0.01)
Data to Be Presented at 2014 San Antonio Breast Cancer Symposium Demonstrate Immune-Stimulatory Properties of Peregrine Pharmaceuticals' Bavituximab in Models of Breast Cancer
Marketwired - Fri Dec 12, 7:00AM CST
Peregrine Pharmaceuticals, Inc. (NASDAQ: PPHM) (NASDAQ: PPHMP), a biopharmaceutical company focused on advancing bavituximab, an investigational immuno-oncology antibody targeting the highly immunosuppressive phosphatidylserine (PS) signaling pathway, today announced preclinical data from recently conducted single agent studies at the 2014 San Antonio Breast Cancer Symposium in San Antonio, Texas being held December 9-13, 2014.
PPHMP: 21.75 (-0.49), PPHM: 1.40 (+0.01)
Peregrine Pharma FQ2 results
Seeking Alpha - at Seeking Alpha - Thu Dec 11, 5:47AM CST
PPHM: 1.40 (+0.01)
Peregrine Pharmaceuticals' (PPHM) CEO Steven King on Q2 2015 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Thu Dec 11, 3:39AM CST
PPHM: 1.40 (+0.01)
Peregrine Pharmaceuticals (PPHM) Q2 2015 Results - Earnings Call Webcast
SA Transcripts - at Seeking Alpha - Wed Dec 10, 3:25PM CST
PPHM: 1.40 (+0.01)
Peregrine Pharmaceuticals EPS in-line, beats on revenue
Seeking Alpha - at Seeking Alpha - Wed Dec 10, 3:04PM CST
PPHM: 1.40 (+0.01)
Peregrine Pharmaceuticals Reports Second Quarter Fiscal Year 2015 Financial Results and Recent Developments
Marketwired - Wed Dec 10, 3:02PM CST
Peregrine Pharmaceuticals, Inc. (NASDAQ: PPHM) (NASDAQ: PPHMP), a biopharmaceutical company focused on advancing bavituximab, a new immuno-oncology antibody targeting the highly immunosuppressive phosphatidylserine (PS) signaling pathway, towards commercialization and providing integrated cGMP clinical and commercial bio-manufacturing services, today announced financial results for the second quarter of fiscal year (FY) 2015 ended October 31, 2014. The company also provided an update on its advancing clinical pipeline and reviewed other corporate developments.
PPHMP: 21.75 (-0.49), PPHM: 1.40 (+0.01)
Avid Bioservices Announces Expansion of cGMP Manufacturing Capacity
Marketwired - Wed Dec 10, 7:06AM CST
Avid Bioservices, Inc, the contract manufacturing subsidiary of Peregrine Pharmaceuticals, Inc. (NASDAQ: PPHM) (NASDAQ: PPHMP), today announced it has initiated an expansion of its biomanufacturing capacity. Avid provides high quality clinical and commercial manufacturing services under cGMP for the biotechnology and biopharmaceutical industries. The new production facility will more than double Avid Bioservices' current manufacturing capacity in a state-of-the-art facility design.
PPHMP: 21.75 (-0.49), PPHM: 1.40 (+0.01)
Peregrine Pharmaceuticals' board to pay USD0.65625 per preferred share dividend
M2 - Wed Dec 10, 6:11AM CST
The board of directors of Peregrine Pharmaceuticals (NASDAQ
PPHMP: 21.75 (-0.49), PPHM: 1.40 (+0.01)
Notable earnings after Wednesday's close
Seeking Alpha - at Seeking Alpha - Tue Dec 09, 4:35PM CST
SIGM: 5.58 (+0.06), RH: 96.97 (-0.16), MW: 43.78 (-0.24), IRET: 8.46 (-0.11), CENT: 8.66 (+0.06), AVNW: 1.52 (+0.01), WTSL: 0.06 (-0.02), PPHM: 1.40 (+0.01), CASY: 89.15 (+0.12), SURG: 4.39 (-0.03)
Peregrine Pharmaceuticals Declares Quarterly Dividend on Its Series E Convertible Preferred Stock
Marketwired - Tue Dec 09, 3:00PM CST
Peregrine Pharmaceuticals, Inc. (NASDAQ: PPHM) (NASDAQ: PPHMP) today announced that its Board of Directors has declared a quarterly cash dividend payment on the Company's 10.50% Series E Convertible Preferred Stock (the "Series E Preferred Stock"
PPHMP: 21.75 (-0.49), PPHM: 1.40 (+0.01)
Peregrine reports December 10
Seeking Alpha - at Seeking Alpha - Wed Dec 03, 3:26PM CST
PPHM: 1.40 (+0.01)
Peregrine Pharmaceuticals to Report Second Quarter Fiscal 2015 Financial Results After Market on December 10, 2014
Marketwired - Wed Dec 03, 3:00PM CST
Peregrine Pharmaceuticals, Inc. (NASDAQ: PPHM) (NASDAQ: PPHMP), a biopharmaceutical company developing first-in-class monoclonal antibodies for the treatment and diagnosis of cancer, today announced that it will report financial results for the second quarter fiscal year (FY) 2015 ended October 31, 2014 on December 10, 2014 after market and will host a conference call and webcast at 1:30 PM Pacific Standard Time (4:30 PM Eastern Standard Time). Peregrine's senior management will discuss financial results for the second quarter ended October 31, 2014 of FY 2015 and will review recent progress of its clinical development programs.
PPHMP: 21.75 (-0.49), PPHM: 1.40 (+0.01)
Molecular Biology Meets Finance: MLV's George Zavoico On Ebola's Silver Lining
Life Sciences Report - Seeking Alpha - Thu Nov 13, 6:59AM CST
A working knowledge of molecular biology is essential for a biotech investor, but it helps when someone with deep knowledge of science and medicine can bring understanding to the people who commit capital to growth ideas. George Zavoico of MLV &...
CERS: 6.49 (+0.29), AGEN: 3.85 (unch), NVAX: 5.81 (+0.18), ALXN: 181.96 (+3.09), PPHM: 1.40 (+0.01), THLD: 2.93 (+0.01), GSK: 42.85 (+0.11), OMER: 22.09 (+0.48)
Phase II Clinical Data Presented at SITC Annual Meeting Support Immunotherapeutic Mechanism of Action of Peregrine Pharmaceuticals' Bavituximab in Liver Cancer
Marketwired - Mon Nov 10, 6:31AM CST
Peregrine Pharmaceuticals, Inc. (NASDAQ: PPHM) (NASDAQ: PPHMP), today announced the presentation of clinical and preclinical data related to the company's immuno-oncology development program and its lead investigational immunotherapy drug candidate bavituximab at the Society for Immunotherapy of Cancer's (SITC) 29th Annual Meeting and Associated Programs. This conference was held November 6-9, 2014 at the Gaylord National Hotel and Convention Center in National Harbor, Maryland. The translational clinical presentation titled: "Correlative Studies of a Phase II Clinical Study of Bavituximab and Sorafenib in Patients with Advanced Hepatocellular Carcinoma (HCC)" was presented Saturday.
PPHMP: 21.75 (-0.49), PPHM: 1.40 (+0.01)
Data to Be Presented at the SITC Annual Meeting Support Synergy of PS-Targeting and Anti-CTLA-4 Immunotherapies to Enhance Anti-Tumor Treatments in Melanoma
Marketwired - Fri Nov 07, 6:45AM CST
Peregrine Pharmaceuticals, Inc. (NASDAQ: PPHM) (NASDAQ: PPHMP), today announced the first of four presentations of clinical and preclinical data related to the company's immuno-oncology development program and its lead investigational immunotherapy drug candidate bavituximab. Data from today's presentation show that the combination of a phosphatidylserine (PS)-targeting antibody equivalent to bavituximab and an antibody targeting the immune checkpoint CTLA-4 yielded statistically significant anti-tumor effects as compared to the anti-CTLA-4 antibody alone. In addition, this combination decreased levels of Arg1, a molecule predominantly expressed by myeloid derived suppressor cells (MDSC) and M2 macrophages; two key cell types that contribute to immunosupressive activity in animal models of melanoma. This presentation will be made at the Society for Immunotherapy of Cancer's (SITC) 29th Annual Meeting and Associated Programs being held November 6-9, 2014 at the Gaylord National Hotel and Convention Center in National Harbor, Maryland.
PPHMP: 21.75 (-0.49), PPHM: 1.40 (+0.01)
Promising Data Presented at the Chicago Multidisciplinary Symposium on Thoracic Oncology From an Investigator-Sponsored Trial of Peregrine Pharmaceuticals' Bavituximab in Combination With Pemetrexed and Carboplatin in Front-Line Non-Small Cell Lung Cancer
Marketwired - Thu Oct 30, 8:42AM CDT
Peregrine Pharmaceuticals, Inc. (NASDAQ: PPHM) (NASDAQ: PPHMP), today announced the presentation of data from the Phase Ib investigator-sponsored trial (IST) of its immunotherapy bavituximab in combination with the chemotherapies pemetrexed and carboplatin in patients with previously untreated, locally advanced or metastatic non-squamous non-small cell lung cancer (NSCLC). Data from this single-arm, open-label, multi-center trial show an overall tumor response (ORR) of 35%, a median progression-free-survival (PFS) of 4.8 months, and a median overall survival (OS) of 12.2 months. Favorable trends in ORR and OS continue to support bavituximab's potential in NSCLC.(1-4) These data are presented in a poster session at the 2014 Chicago Multidisciplinary Symposium on Thoracic Oncology being held at the Marriott Downtown Chicago Magnificent Mile in Chicago, Illinois.
PPHMP: 21.75 (-0.49), PPHM: 1.40 (+0.01)
Biotech Stocks Technical Data - CytRx, Vertex Pharma, Alexion Pharma, Peregrine Pharma, and StemCells
PR Newswire - Fri Oct 24, 8:00AM CDT
Investor-Edge has initiated coverage on the following equities: CytRx Corporation (NASDAQ: CYTR), Vertex Pharmaceuticals Inc. (NASDAQ: VRTX), Alexion Pharmaceuticals Inc. (NASDAQ: ALXN), Peregrine Pharmaceuticals Inc. (NASDAQ: PPHM), and StemCells Inc. (NASDAQ: STEM). Free research on these five companies can be accessed at: http://investor-edge.com/register. The US markets on Thursday, October 23, 2014, ended on a positive note as the Dow Jones Industrial Average finished at 16,677.90, up 1.32% and the NASDAQ Composite closed at 4,452.79, up 1.60%. The S&P 500 finished the session 1.23% higher at 1,950.82. During the trading session, eight out of ten sectors finished on a higher note. The S&P 500 Health Care Sector Index ended the day at 744.13, up 1.75%, with the index advancing 3.42% in the previous three months. Register for your complimentary reports on these five stocks at:
VRTX: 115.15 (+1.40), STEM: 0.90 (+0.03), ALXN: 181.96 (+3.09), CYTR: 2.58 (+0.03), PPHM: 1.40 (+0.01)
Peregrine Pharmaceuticals (PPHM) Jumps: Stock Rises 10.7% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Oct 16, 8:39AM CDT
Peregrine Pharmaceuticals, Inc. (PPHM) was a big mover last session, as its shares rose nearly 11% on the day.
MACK: 10.91 (+0.36), MYGN: 36.50 (+0.28), HALO: 9.34 (+0.31), PPHM: 1.40 (+0.01)
Nasdaq stocks posting largest volume increases
AP - Wed Oct 15, 5:08PM CDT
NEW YORK (AP) — A look at the 10 biggest volume gainers on Nasdaq at the close of trading:
CHFN: 11.36 (-0.07), ARTW: 4.97 (+0.02), PPHM: 1.40 (+0.01), PENX: 18.83 (+0.04), LAKE: 8.94 (+0.07), EXAC: 22.68 (+0.24), NAUH: 2.93 (+0.11), COVS: 2.73 (+0.08), UPIP: 1.05 (+0.03), JAXB: 12.26 (+0.96), CEMI: 3.98 (+0.08), DENN: 9.96 (+0.05)